Tern Plc Mathew Scherba seconded to Konektio

TERN

Tern Plc (LON:TERN), the company focused on value creation from Internet of Things (“IoT”) technology businesses, has announced that it has agreed with the board of InVMA Limited, trading as Konektio, of which Tern currently owns 36.8% of the equity, and Konektio’s other investors, that Mathew Scherba, a director of Tern, will join the Konektio executive team for an initial two month period, with an option, on the mutual agreement of both parties, to further extend the secondment, to assist with the development of the Konektio business.

Mathew Scherba, will remain a director of Tern, fulfilling his duties and responsibilities at Tern, but will devote the majority of his time to assisting Konektio as it executes its growth plans, in particular the completion of the productisation of the next release of AssetMinder®, its modular, industry 4.0, IoT (software as a service) SaaS platform.  The agreement for Mr Scherba’s services will see Tern receive payments from Konektio, equal to the basic salary he is paid by Tern for the time he commits to Konektio.

Commenting Al Sisto, CEO of Tern, said:

“Tern’s hands-on approach with its portfolio companies is key to creating further value so that Tern shareholders can ultimately benefit from this value.  We are therefore pleased, with the agreement and support of Konektio’s other investors, to be able to provide Konektio with the benefit of Mathew Scherba’s skills and experience to help drive the completion of the productisation of their next exciting release of AssetMinder® and further expand their routes to market.

“All of the team at Tern continue to focus, in a hands-on manner, on maximising the investment value for Tern shareholders from our portfolio companies and I look forward to making further announcements on their progress in due course.”

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

CAR-T therapy brings new approach to multiple myeloma treatment

CAR-T therapy is being used in multiple myeloma and is being studied earlier in the treatment pathway, with research focused on improving durability, safety and access.

Tern cuts H1 loss by 60% as portfolio growth and funding strengthen

Tern reduced its first-half loss by 60%, with net asset value improving and further fundraising strengthening the balance sheet. Additional funding has supported Talking Medicines and Device Authority, while continued progress across the portfolio provides further scope for value creation.

AI control of machines creates a new market for device trust

AI is beginning to control physical machines, increasing demand for technology that can verify device identity before those machines are allowed to act.

Peptide drug development expands beyond GLP-1

GLP-1 success is widening interest in peptide drug development, with the next phase focused on proving clinical value across new therapeutic areas.

Tern Plc announces 90% take-up of Open Offer

Tern Plc has received valid acceptances for 50.9 million Open Offer Shares, representing approximately 90% of the shares available. The fully underwritten offer will raise approximately £509,368 before expenses, with admission of the new shares expected on 24 September 2026.

Talking Medicines moves to capture pharma demand for better patient intelligence

Tighter US pharma advertising rules could increase demand for patient intelligence, supporting the relevance of Talking Medicines’ DrugVoice platform.

Search